Page 8 - Geneos Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance Personalized Cancer Immunotherapy Programs Geneos expands its lead program for treating patients with advanced hepatocellular carcinoma Geneos adds to its leadership team News provided by Share this article Share this article PLYMOUTH MEETING, Pa., March 3, 2021 /PRNewswire/ Geneos Therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer, announced today that it has closed its Series A1 round, raising $12 million in financing. The financing was led by Korea Investment Partners (KIP) – Global Bio Fund with strong participation from all existing Series A investors including, notably, Santé Ventures and Inovio Pharmaceuticals, Inc. (NASDAQ: INO). The new investment follows the previously announced initial financing of $10.5 million in February 2019. In conjunction with the financing, Mr. Sangwoo Lee, Managing Director Korea In

United statesSouth koreaHakim hammachSangwoo leeAlfredo perales puchaltNiranjany sardesaiUnited states incGlobal bio fundInovio pharmaceuticalsInovio pharmaceuticals incResearch developmentBusiness developmentKorea investment partnersManaging director korea investment partnersGeneo boardChief executive officer